After receiving Food and Drug Administration approval for its Parkinson's disease psychosis drug, Acadia Pharmaceuticals (ACAD - Get Report) is an attractive target for strategic buyers and could go for as much as $6 billion, analysts say.
The drug, Nuplazid, is used to treat delusions and hallucinations in patients with psychosis caused by Parkinson's disease, a progressive disease that affects the nervous system and is known for causing tremors. Acadia is expected to report earnings today after market close. The consensus earnings per share forecast is a loss of 4 cents per share.
The drug, Nuplazid, is used to treat delusions and hallucinations in patients with psychosis caused by Parkinson's disease, a progressive disease that affects the nervous system and is known for causing tremors. Acadia is expected to report earnings today after market close. The consensus earnings per share forecast is a loss of 4 cents per share.
